Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
53,514,204
-
Total 13F shares
-
12,460,895
-
Share change
-
-3,800,117
-
Total reported value
-
$13,460,257
-
Price per share
-
$1.08
-
Number of holders
-
30
-
Value change
-
-$2,778,261
-
Number of buys
-
10
-
Number of sells
-
13
Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q1 2024
As of 31 Mar 2024,
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,460,895 shares.
The largest 10 holders included
Bain Capital Life Sciences Investors, LLC, FMR LLC, TAKEDA PHARMACEUTICAL CO LTD, RiverVest Venture Management LLC, Rock Springs Capital Management LP, Atlas Venture Life Science Advisors, LLC, VANGUARD GROUP INC, Balyasny Asset Management L.P., RENAISSANCE TECHNOLOGIES LLC, and MORGAN STANLEY.
This page lists
30
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.